

CRISPR-Cas based TB detection system

Domain: Diagnostic (Assay/Kit)

About Technology: This detection system performs heat-based lysis and column DNA extraction (RapidBact), followed by multiplex PCR and CRISPR-Cas12a detection (Glow-TBPCR). Cas12a, guided by TB-specific gRNAs, produces a fluorescence signal upon target recognition. The RapidGlow device supports incubation and real-time fluorescence detection, with RGLOW software enabling automated data analysis

Intended Use: Diagnosis of tuberculosis

Advantages:

- Rapid DNA extraction from as little as 60 µl of sputum
- Multiplex detection of 3 TB genes; ultra-sensitive (LOD ~1 copy/µl)
- High-throughput, and cost-effective alternative to centralized diagnostics

IP Status: Filed (Indian Patent Application No. - 202411016083, 202411043686, 202511026919)

Technology Transfer Status: Transferred to companies on Non-Exclusive basis

Institute(s): ICMR-Regional Medical Research Centre (RMRCNE)

Inventor(s): Dr. Md. Atique Ahmed

Pictorial Representation of technology/Product



RapidBact:
DNA Extraction kit
(Patent Application No. 202511026919)



Glow-TB_{PCR}:
PCR-CRISPR-Cas based
detection kit
(Patent Application No. 202411043686)



RapidGlow: Incubation-cum-
fluorescence detection device
(Patent Application No. 202411016083)



RGLOW: Data acquisition and
result analysis software
(Copyright applied)

For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in